870274-21-8

Basic information

• Product Name: ethyl 2-(5-bromo-2-nitrophenyl)acetate
• Synonyms: ethyl 2-(5-bromo-2-nitrophenyl)acetate;BENZENEACETIC ACID, 5-BROMO-2-NITRO-, ETHYL ESTER;5-BroMo-2-nitro-phenylacetic acid ethyl ester
• CAS NO: 870274-21-8
• Molecular Formula: C₁₀H₁₀BrNO₄
• Molecular Weight: 288.096
• Mol File: 870274-21-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-(5-bromo-2-nitrophenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(5-bromo-2-nitrophenyl)acetate(870274-21-8)
• EPA Substance Registry System: ethyl 2-(5-bromo-2-nitrophenyl)acetate(870274-21-8)

Safety Data

• Hazardous Substances Data: 870274-21-8(Hazardous Substances Data)

Usage

General Description

Ethyl 2-(5-bromo-2-nitrophenyl)acetate is a chemical compound with the molecular formula C10H10BrNO4. It is a yellow to brown solid, commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. ethyl 2-(5-bromo-2-nitrophenyl)acetate is a versatile and useful building block for the preparation of various organic compounds due to its reactivity and functionality. It is also used in the manufacturing of dyes and pigments. Ethyl 2-(5-bromo-2-nitrophenyl)acetate can be synthesized through the esterification of 5-bromo-2-nitrobenzoic acid with ethyl acetate in the presence of a catalytic amount of sulfuric acid, followed by purification and isolation. It is important to handle this compound with care, as it is considered harmful if swallowed or inhaled and can cause skin and eye irritation upon contact.

Upstream product

• 105-39-5 chloroacetic acid ethyl ester 
• 586-78-7 para-nitrophenyl bromide 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 64-17-5 ethanol 
• 124840-61-5 2-(5-bromo-2-nitrophenyl)aceticacid 

Downstream Products

• 870274-20-7 [5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-acetic acid ethyl ester 

Relevant articles and documents

COMPOUNDS AND METHODS FOR MODULATING SPLICING

The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives

The dysfunction and mutual compensatory activation of RAF-MEK-ERK and PI3K-PDK1-AKT pathways have been demonstrated as the hallmarks in several primary and recurrent cancers. The strategy of concurrent blocking of these two pathways shows clinical merits on effective cancer therapy, such as combinatory treatments and dual-pathway inhibitors. Herein, we report a novel prototype of dual-pathway inhibitors by means of merging the core structural scaffolds of a MEK1 inhibitor and a PDK1 inhibitor. A library of 43 compounds that categorized into three series (Series I–III) was synthesized and tested for antitumor activity in lung cancer cells. The results from structure-activity relationship (SAR) analysis showed the following order of antitumor activity that 3-hydroxy-5-(phenylamino) indolone (Series III) > 3-alkenyl-5-(phenylamino) indolone (Series I) > 3-alkyl-5-(phenylamino) indolone (Series II). A lead compound 9za in Series III showed most potent antitumor activity with IC50 value of 1.8 ± 0.8 μM in A549 cells. Moreover, antitumor mechanism study demonstrated that 9za exerted significant apoptotic effect, and cellular signal pathway analysis revealed the potent blockage of phosphorylation levels of ERK and AKT in RAF-MEK-ERK and PI3K-PDK1-AKT pathways, respectively. The results reported here provide robust experimental basis for the discovery and optimization of dual pathway agents for anti-lung cancer therapy.

Tricyclic oxazolidone comound, and preparation method and use thereof

The invention relates to a novel tricyclic oxazolidone comound, and a preparation method and a use thereof, and concretely discloses a compound with the structure represented by formula I, an enantiomer, a diastereomer or a raceme thereof or a mixture of the enantiomer, the diastereomer and the raceme, or a pharmaceutically acceptable salt thereof. The formula I is shown in the specification. The invention also discloses a preparation method of the compound, and an application of the compound in FXa target related disease treatment drugs.